Ekin, Omer;
Calis, Mert;
Aliyev, Ali;
Yar, Seda Atiye;
Korkusuz, Petek;
Bilgic, Elif;
Aydin, Halil Murat;
Celik, Hakan Hamdi;
Ozgur, Figen;
Vargel, Ibrahim
Poly(L-Lactide)/Poly(∊-Caprolactone) and Collagen/β-Tricalcium Phosphate Scaffolds for the Treatment of Critical-Sized Rat Alveolar Defects: A Microtomographic, Molecular-Biological, and Histological Study
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Poly(L-Lactide)/Poly(∊-Caprolactone) and Collagen/β-Tricalcium Phosphate Scaffolds for the Treatment of Critical-Sized Rat Alveolar Defects: A Microtomographic, Molecular-Biological, and Histological Study
Contributor:
Ekin, Omer;
Calis, Mert;
Aliyev, Ali;
Yar, Seda Atiye;
Korkusuz, Petek;
Bilgic, Elif;
Aydin, Halil Murat;
Celik, Hakan Hamdi;
Ozgur, Figen;
Vargel, Ibrahim
imprint:
SAGE Publications, 2016
Published in:The Cleft Palate-Craniofacial Journal
Description:
<jats:sec><jats:title>Objective</jats:title><jats:p> To determine the efficacy of a newly developed scaffold (col/β-TCP) in a preclinical rat model as compared with the gold standard treatment (autograft) and control scaffolds (PLLA/PCL). </jats:p></jats:sec><jats:sec><jats:title>Design</jats:title><jats:p> Fifty-six Sprague-Dawley rats were randomized into four experimental groups, and critical-sized alveolar defects (7 × 4 × 3 mm) were created in each animal. Group A was the blank defect group, group B received autograft, group C received col/β-TCP scaffolds, and group D received PLLA/PCL blend scaffolds to fill the bone defects. New bone formation was assessed radiomorphometrically, histomorphometrically, and molecular-biologically at 1 and 4 months following surgery. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Radiomorphometrically, the best new bone volume rate at 1 month (43.7%) and 4 months (45.4%) was observed in the autograft group, and the difference was significantly higher than in the other three groups ( P ≤ .005, P ≤ .001, P ≤ .001 for 1 month and P = .004, P ≤ .001, P ≤ .001 for 4 months). Even though the new bone volume rate in the col/β-TCP group (21.5%) was higher than that of the PLLA/PCL group (18.2%), the difference was not significant ( P = .08). Molecular-genetic analysis revealed significantly higher BSP and ALP gene expression levels in the autograft and col/β-TCP groups than in the blank defect group ( P = .002 and P = .004). </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> The engineered tissue scaffolds described herein have great potential as an alternative treatment option when cost, donor region morbidity, and duration of hospitalization are considered. </jats:p></jats:sec>